Traders See Bullish Options Activity Celgene Corporation

 Traders See Bullish Options Activity Celgene Corporation

In today’s session Celgene Corporation (CELG) registered an unusually high (2,658) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the April, 2017 call, expecting serious CELG increase. With 2,658 contracts traded and 24184 open interest for the Apr, 17 contract, it seems this is a quite bullish bet. The option with symbol: CELG170421C00120000 closed last at: $9.3 or 141.6% up. About 1.34 million shares traded hands. Celgene Corporation (NASDAQ:CELG) has risen 16.62% since April 11, 2016 and is uptrending. It has outperformed by 10.47% the S&P500.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Out of 21 analysts covering Celgene Corporation (NASDAQ:CELG), 17 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 81% are positive. $190 is the highest target while $83 is the lowest. The $136.89 average target is 15.33% above today’s ($118.69) stock price. Celgene Corporation has been the topic of 38 analyst reports since July 21, 2015 according to StockzIntelligence Inc. JMP Securities maintained the shares of CELG in a report on Wednesday, March 9 with “Market Outperform” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, July 24. UBS maintained the stock with “Buy” rating in Friday, July 24 report. The firm earned “Strong-Buy” rating on Tuesday, September 1 by Raymond James. The rating was initiated by Credit Suisse with “Outperform” on Wednesday, January 20. Cowen & Co maintained Celgene Corporation (NASDAQ:CELG) on Wednesday, August 12 with “Outperform” rating. UBS maintained Celgene Corporation (NASDAQ:CELG) on Friday, November 6 with “Buy” rating. The stock of Celgene Corporation (NASDAQ:CELG) earned “Overweight” rating by JP Morgan on Thursday, October 1. The rating was initiated by Citigroup on Thursday, February 25 with “Buy”. Jefferies maintained Celgene Corporation (NASDAQ:CELG) on Wednesday, October 5 with “Buy” rating.

According to Zacks Investment Research, “Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.”

Insitutional Activity: The institutional sentiment increased to 0.99 in 2016 Q2. Its up 0.06, from 0.93 in 2016Q1. The ratio is positive, as 70 funds sold all Celgene Corporation shares owned while 411 reduced positions. 60 funds bought stakes while 418 increased positions. They now own 587.22 million shares or 5.24% less from 619.66 million shares in 2016Q1.
Rhumbline Advisers holds 0.35% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 1.19 million shares. Glenview Bank Tru Dept last reported 12,400 shares in the company. Regions last reported 0.26% of its portfolio in the stock. Cwm Limited Liability Co accumulated 0.49% or 68,218 shares. Ameritas Inv Partners last reported 64,928 shares in the company. Shaker Invs Llc Oh holds 0.63% or 7,023 shares in its portfolio. Jolley Asset Mgmt Limited Liability Com last reported 0.1% of its portfolio in the stock. Intersect Cap Lc has 0.15% invested in the company for 2,580 shares. Moreover, Peddock Capital Advisors Limited Co has 0.78% invested in Celgene Corporation (NASDAQ:CELG) for 12,451 shares. Comerica Secs Inc holds 0.28% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 4,351 shares. Dillon & Assocs accumulated 41,955 shares or 1.91% of the stock. Moreover, Korea Investment Corp has 0.36% invested in Celgene Corporation (NASDAQ:CELG) for 608,770 shares. Arete Wealth Advsrs Ltd Llc holds 0.19% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 3,096 shares. Tower Ltd Liability Corp (Trc) last reported 6,786 shares in the company. Argentus Cap Management Limited Liability Co reported 1,737 shares or 0.07% of all its holdings.

Insider Transactions: Since July 28, 2016, the stock had 0 insider buys, and 8 insider sales for $31.92 million net activity. Friedman Michael A had sold 18,600 shares worth $2.16 million on Wednesday, November 9. The insider HUGIN ROBERT J sold $11.00M. $4.92M worth of Celgene Corporation (NASDAQ:CELG) was sold by CASEY MICHAEL D on Monday, August 22. MARIO ERNEST sold $1.64 million worth of stock or 15,000 shares. KAPLAN GILLA sold $1.03M worth of stock. BARKER RICHARD W had sold 20,000 shares worth $2.22M. The insider LOUGHLIN JAMES J sold 27,500 shares worth $3.14 million.

Celgene Corporation is a biopharmaceutical company. The company has a market cap of $92.77 billion. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. It has a 44.98 P/E ratio. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin).

CELG Company Profile

Celgene Corporation (Celgene), incorporated on April 17, 1986, is a biopharmaceutical company. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

More important recent Celgene Corporation (NASDAQ:CELG) news were published by: Profitconfidential.com which released: “Celgene Corporation: What a Trump Win Means for CELG Stock” on November 09, 2016, also Fool.com published article titled: “2 Reasons Celgene Corporation’s Future Just Got Brighter”, Fool.com published: “Celgene Corporation Is Firing on All Cylinders” on October 28, 2016. More interesting news about Celgene Corporation (NASDAQ:CELG) was released by: Nasdaq.com and their article: “Celgene Corporation Reveals 25% Rise In Q3 Bottom Line” with publication date: October 27, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment